Gene and cell therapies offer new hope for treating many genetic diseases and cancers, but their progress is limited by a major bottleneck: producing the viral carriers that deliver these therapies into human cells is complex, costly, and difficult to scale. Vectopia is developing a new production platform based on engineered cell lines that already contain all the elements needed to create these viral vectors. Instead of relying on complicated multi-step manufacturing processes, production can simply be activated when needed, making it faster, more consistent, and easier to scale. By simplifying this critical step, Vectopia aims to accelerate the development and availability of next-generation gene and cell therapies.